Fujifilm Diosynth Biotechnologies broke ground in August of 2020 on the $55 million Advanced Therapies Innovation Center in College Station, Texas. Representing an expansion of Fujifilm's cGMP manufacturing campus, the 60,000-sf facility will feature dedicated labs for process development and innovation. Research environments with BSL-2 capabilities will integrate advanced technologies for upstream, downstream, and analytical development. Housing multiple 500-liter and 2000-liter bioreactors, the project will further the company's initiative to provide comprehensive fill-to-finish services ranging from pre-clinical through commercial launch. The center will triple Fujifilm's gene therapy development capacity when operations commence in fall of 2021.